Which has higher valuation and earnings, MDLN or SNN?

Smith & Nephew SNATS has lower revenue, but higher earnings than Medline. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medline $28.43B 1.57 N/A N/A N/A Smith & Nephew SNATS $6.16B 2.07 $625M N/A N/A

Is MDLN or SNN more profitable?

Company Net Margins Return on Equity Return on Assets Medline N/A N/A N/A Smith & Nephew SNATS N/A N/A N/A

Does the media prefer MDLN or SNN?

In the previous week, Medline had 8 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 9 mentions for Medline and 1 mentions for Smith & Nephew SNATS. Medline's average media sentiment score of 0.57 beat Smith & Nephew SNATS's score of 0.00 indicating that Medline is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medline 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, GEHC or SNN?

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GE HealthCare Technologies $20.98B 1.34 $2.08B $4.18 14.77 Smith & Nephew SNATS $6.16B 2.07 $625M N/A N/A

Does the media refer more to GEHC or SNN?

In the previous week, GE HealthCare Technologies had 14 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 15 mentions for GE HealthCare Technologies and 1 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 1.04 beat Smith & Nephew SNATS's score of 0.00 indicating that GE HealthCare Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PHG or SNN?

Smith & Nephew SNATS has a consensus target price of $30.93, suggesting a potential upside of 3.31%. Given Smith & Nephew SNATS's stronger consensus rating and higher probable upside, analysts plainly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Smith & Nephew SNATS 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable valuation and earnings, PHG or SNN?

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Koninklijke Philips $17.64B 1.38 $1.01B $1.17 21.65 Smith & Nephew SNATS $6.16B 2.07 $625M N/A N/A

Does the media refer more to PHG or SNN?

In the previous week, Koninklijke Philips had 2 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 3 mentions for Koninklijke Philips and 1 mentions for Smith & Nephew SNATS. Koninklijke Philips' average media sentiment score of 0.20 beat Smith & Nephew SNATS's score of 0.00 indicating that Koninklijke Philips is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, ZBH or SNN?

Zimmer Biomet has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zimmer Biomet $8.23B 2.00 $705.20M $3.85 22.07 Smith & Nephew SNATS $6.16B 2.07 $625M N/A N/A

Does the media refer more to ZBH or SNN?

In the previous week, Zimmer Biomet had 16 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 17 mentions for Zimmer Biomet and 1 mentions for Smith & Nephew SNATS. Zimmer Biomet's average media sentiment score of 1.05 beat Smith & Nephew SNATS's score of 0.00 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 11 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SNN or SOLV?

Solventum has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.07 $625M N/A N/A Solventum $8.33B 1.62 $1.56B $8.16 9.56

Does the media favor SNN or SOLV?

In the previous week, Solventum had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for Solventum and 1 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 0.38 beat Smith & Nephew SNATS's score of 0.00 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solventum 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Smith & Nephew SNATS (SNN) Competitors

$29.94 +0.58 (+1.96%)

As of 02:04 PM Eastern

Compare

SNN vs. MDLN, GEHC, PHG, ZBH, and SOLV

Should you buy Smith & Nephew SNATS stock or one of its competitors? MarketBeat compares Smith & Nephew SNATS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Smith & Nephew SNATS include Medline (MDLN), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), and Solventum (SOLV). These companies are all part of the "medical equipment" industry.

How does Smith & Nephew SNATS compare to Medline?

Medline (NASDAQ:MDLN) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.8% of Medline shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Medline presently has a consensus price target of $50.54, suggesting a potential upside of 49.09%. Smith & Nephew SNATS has a consensus price target of $30.93, suggesting a potential upside of 3.31%. Given Medline's stronger consensus rating and higher probable upside, equities research analysts clearly believe Medline is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Smith & Nephew SNATS has lower revenue, but higher earnings than Medline.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.57	N/A	N/A	N/A
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Smith & Nephew SNATS	N/A	N/A	N/A

In the previous week, Medline had 8 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 9 mentions for Medline and 1 mentions for Smith & Nephew SNATS. Medline's average media sentiment score of 0.57 beat Smith & Nephew SNATS's score of 0.00 indicating that Medline is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Medline beats Smith & Nephew SNATS on 6 of the 9 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

82.1% of GE HealthCare Technologies shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.4% of GE HealthCare Technologies shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.1%. GE HealthCare Technologies pays out 3.3% of its earnings in the form of a dividend. GE HealthCare Technologies has raised its dividend for 1 consecutive years.

GE HealthCare Technologies currently has a consensus price target of $80.21, indicating a potential upside of 29.96%. Smith & Nephew SNATS has a consensus price target of $30.93, indicating a potential upside of 3.31%. Given GE HealthCare Technologies' higher possible upside, equities research analysts plainly believe GE HealthCare Technologies is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	0 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, GE HealthCare Technologies had 14 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 15 mentions for GE HealthCare Technologies and 1 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 1.04 beat Smith & Nephew SNATS's score of 0.00 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GE HealthCare Technologies has a net margin of 9.10% compared to Smith & Nephew SNATS's net margin of 0.00%. GE HealthCare Technologies' return on equity of 20.46% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.10%	20.46%	5.73%
Smith & Nephew SNATS	N/A	N/A	N/A

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.98B	1.34	$2.08B	$4.18	14.77
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A

GE HealthCare Technologies has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Summary

GE HealthCare Technologies beats Smith & Nephew SNATS on 12 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$17.64B	1.38	$1.01B	$1.17	21.65
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A

Koninklijke Philips has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Koninklijke Philips pays an annual dividend of $0.86 per share and has a dividend yield of 3.4%. Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.1%. Koninklijke Philips pays out 73.5% of its earnings in the form of a dividend.

In the previous week, Koninklijke Philips had 2 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 3 mentions for Koninklijke Philips and 1 mentions for Smith & Nephew SNATS. Koninklijke Philips' average media sentiment score of 0.20 beat Smith & Nephew SNATS's score of 0.00 indicating that Koninklijke Philips is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Koninklijke Philips has a net margin of 5.49% compared to Smith & Nephew SNATS's net margin of 0.00%. Koninklijke Philips' return on equity of 13.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
Smith & Nephew SNATS	N/A	N/A	N/A

Smith & Nephew SNATS has a consensus target price of $30.93, suggesting a potential upside of 3.31%. Given Smith & Nephew SNATS's stronger consensus rating and higher probable upside, analysts plainly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

13.7% of Koninklijke Philips shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Koninklijke Philips beats Smith & Nephew SNATS on 9 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Zimmer Biomet has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.00	$705.20M	$3.85	22.07
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A

In the previous week, Zimmer Biomet had 16 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 17 mentions for Zimmer Biomet and 1 mentions for Smith & Nephew SNATS. Zimmer Biomet's average media sentiment score of 1.05 beat Smith & Nephew SNATS's score of 0.00 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	11 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zimmer Biomet has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Zimmer Biomet has a net margin of 9.05% compared to Smith & Nephew SNATS's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Smith & Nephew SNATS	N/A	N/A	N/A

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.1%. Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.1%. Zimmer Biomet pays out 24.9% of its earnings in the form of a dividend.

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zimmer Biomet presently has a consensus price target of $102.70, indicating a potential upside of 20.85%. Smith & Nephew SNATS has a consensus price target of $30.93, indicating a potential upside of 3.31%. Given Zimmer Biomet's higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Zimmer Biomet beats Smith & Nephew SNATS on 11 of the 16 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Solventum?

Smith & Nephew SNATS (NYSE:SNN) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Solventum has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A
Solventum	$8.33B	1.62	$1.56B	$8.16	9.56

In the previous week, Solventum had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for Solventum and 1 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 0.38 beat Smith & Nephew SNATS's score of 0.00 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solventum	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

25.6% of Smith & Nephew SNATS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Comparatively, 0.2% of Solventum shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Solventum has a net margin of 17.33% compared to Smith & Nephew SNATS's net margin of 0.00%. Solventum's return on equity of 23.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Solventum	17.33%	23.51%	7.63%

Smith & Nephew SNATS currently has a consensus price target of $30.93, suggesting a potential upside of 3.31%. Solventum has a consensus price target of $84.25, suggesting a potential upside of 8.01%. Given Solventum's higher possible upside, analysts clearly believe Solventum is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Smith & Nephew SNATS has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Solventum has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Summary

Solventum beats Smith & Nephew SNATS on 10 of the 14 factors compared between the two stocks.

Get Smith & Nephew SNATS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNN vs. The Competition

Export

Metric	Smith & Nephew SNATS	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$12.78B	$7.85B	$6.26B	$23.14B
Dividend Yield	3.17%	2.56%	2.69%	4.09%
P/E Ratio	N/A	15.36	22.42	31.05
Price / Sales	2.07	5.66	548.01	14.78
Price / Cash	8.60	17.23	42.31	24.78
Price / Book	2.40	3.53	9.82	4.68
Net Income	$625M	$224.05M	$3.56B	$1.07B
7 Day Performance	-0.75%	-1.22%	-1.17%	-0.46%
1 Month Performance	-4.04%	0.23%	3.71%	0.43%
1 Year Performance	2.75%	-0.04%	27.28%	25.81%

Smith & Nephew SNATS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNN Smith & Nephew SNATS	1.8213 of 5 stars	$29.94 +2.0%	$30.93 +3.3%	+0.8%	$12.78B	$6.16B	N/A	16,988
MDLN Medline	3.7783 of 5 stars	$33.94 -7.2%	$50.65 +49.2%	N/A	$48.03B	$28.43B	N/A	43,000	Analyst Forecast
GEHC GE HealthCare Technologies	4.9349 of 5 stars	$61.87 -0.7%	$80.21 +29.6%	-11.6%	$28.36B	$20.63B	14.95	54,000	Positive News
PHG Koninklijke Philips	2.4442 of 5 stars	$25.56 -3.2%	N/A	+11.5%	$25.41B	$20.17B	22.01	65,340
ZBH Zimmer Biomet	4.5999 of 5 stars	$83.68 +1.6%	$102.70 +22.7%	-8.1%	$15.93B	$8.41B	21.51	17,000	News Coverage Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SNN) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Smith & Nephew SNATS (SNN) Competitors

SNN vs. MDLN, GEHC, PHG, ZBH, and SOLV

How does Smith & Nephew SNATS compare to Medline?

Summary

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Summary

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Summary

How does Smith & Nephew SNATS compare to Zimmer Biomet?

Summary

How does Smith & Nephew SNATS compare to Solventum?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Smith & Nephew SNATS (SNN) Competitors

SNN vs. MDLN, GEHC, PHG, ZBH, and SOLV

How does Smith & Nephew SNATS compare to Medline?

Do institutionals & insiders have more ownership in MDLN or SNN?

Do analysts prefer MDLN or SNN?

Which has higher valuation and earnings, MDLN or SNN?

Is MDLN or SNN more profitable?

Does the media prefer MDLN or SNN?

Summary

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Do institutionals & insiders have more ownership in GEHC or SNN?

Is GEHC or SNN a better dividend stock?

Do analysts prefer GEHC or SNN?

Does the media refer more to GEHC or SNN?

Is GEHC or SNN more profitable?

Which has better valuation & earnings, GEHC or SNN?

Which has more risk & volatility, GEHC or SNN?

Summary

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Which has preferable valuation and earnings, PHG or SNN?

Which has more risk and volatility, PHG or SNN?

Is PHG or SNN a better dividend stock?

Does the media refer more to PHG or SNN?

Is PHG or SNN more profitable?

Do analysts recommend PHG or SNN?

Do insiders & institutionals have more ownership in PHG or SNN?

Summary

How does Smith & Nephew SNATS compare to Zimmer Biomet?

Which has better valuation & earnings, ZBH or SNN?

Does the media refer more to ZBH or SNN?

Which has more risk & volatility, ZBH or SNN?

Is ZBH or SNN more profitable?

Is ZBH or SNN a better dividend stock?

Do institutionals and insiders hold more shares of ZBH or SNN?

Do analysts rate ZBH or SNN?

Summary

How does Smith & Nephew SNATS compare to Solventum?

Which has higher valuation & earnings, SNN or SOLV?

Does the media favor SNN or SOLV?

Do institutionals & insiders have more ownership in SNN or SOLV?

Is SNN or SOLV more profitable?

Do analysts prefer SNN or SOLV?

Which has more volatility & risk, SNN or SOLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools